Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States - ISS-G20 Laboratorium Repository

Three COVID-19 vaccinespdf icon are currently approved under a Biologics License Application (BLA) or authorized under an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) (Table 1) (Box 1):

• Pfizer-BioNTech COVID-19 Vaccine/COMIRNATY (hereafter referred to as Pfizer-BioNTech in this document) (1)
• Moderna COVID-19 Vaccine/SPIKEVAX (hereafter referred to as Moderna in this document) (2)
• Janssen (Johnson & Johnson) COVID-19 Vaccine (hereafter referred to as Janssen in this document)

For primary and booster vaccination for all populations, an mRNA COVID-19 vaccine series (i.e., Pfizer-BioNTech or Moderna) is preferred over the Janssen COVID-19 Vaccine. The mRNA COVID-19 vaccines are feasible for use in most vaccine-eligible populations or settings. However, offering the Janssen COVID-19 Vaccine is preferable to not providing any COVID-19 vaccine.

The Pfizer-BioNTech and Moderna vaccines are lipid nanoparticle-formulated, nucleoside-modified mRNA vaccines encoding the prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. The Janssen COVID-19 Vaccine is a recombinant, replication-incompetent adenovirus type 26 (Ad26) vector encoding the stabilized prefusion spike glycoprotein of SARS-CoV-2. None of the currently FDA-approved or FDA-authorized COVID-19 vaccines are live-virus vaccines.

Entire content available on: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html